Greenwich Rx recall infographic showing 31 compounded injectable formulations recalled over sterility concerns

Greenwich Rx Recall: Compounded Semaglutide, Tirzepatide and Peptide Shots Pulled Nationwide

The Greenwich Rx recall announced on November 20, 2026 pulls specific lots of compounded injectable drugs, including semaglutide, tirzepatide, BPC-157 and a long list of other peptide shots, that the Tomball, Texas pharmacy dispensed nationwide between August 10 and September 21, 2026. The pharmacy says the products may not be sterile, a concern that surfaced after an FDA inspection. Some of the recalled vials were made for a second pharmacy, Clove Rx, so patients who never dealt with Greenwich Rx directly may still be affected.

Key takeaways on the Greenwich Rx recall

  • Greenwich Rx, a 503A compounding pharmacy, is recalling lots of compounded sterile injectables that are still within their beyond-use dates, down to the consumer level.
  • The reason given is a potential lack of sterility assurance, identified after an FDA inspection and the pharmacy’s own review.
  • By our count the published recall list spans 31 product formulations, including four compounded tirzepatide blends and three compounded semaglutide blends.
  • Affected products were dispensed nationwide from August 10 to September 21, 2026, through Greenwich Rx and through Clove Rx.
  • No contamination has been found and no adverse events have been reported so far, according to the company. Patients are told to stop using affected vials and discard them.

What was recalled and why it matters

Compounding pharmacies mix drugs for individual patients rather than mass-producing them under a full drug approval. A 503A pharmacy like Greenwich Rx is regulated mainly by state pharmacy boards, with FDA oversight on specific requirements. When the medicine is an injection, sterility is the single most important quality attribute: a needle bypasses the skin’s defences and delivers whatever is in the vial straight into tissue.

The company’s risk statement is blunt. It warns that a drug meant to be sterile that is not sterile “could result in serious infections, which may be life threatening.” It also stresses that it has not found evidence of contamination in the recalled products and is acting as a precaution. That distinction matters: this is a process problem flagged during an inspection, not a confirmed outbreak.

Recalled product groups at a glance

Product groupExamples on the recall listFormulations listed
Compounded GLP-1 weight-loss drugsTirzepatide with B12, glycine, L-carnitine or methylcobalamin; semaglutide with B12, glycine or methylcobalamin7
BPC-157 and TB-500 blendsBPC-157; BPC-157/TB-500; blends with GHK-Cu and KPV; TB-500 alone6
Growth hormone secretagoguesCJC-1295/Ipamorelin, sermorelin, tesamorelin, tesamorelin/ipamorelin, MOTS-C/tesamorelin5
Other peptidesGHK-Cu, epithalon, DSIP, MOTS-C, PT-141, thymosin alpha-1, Semax/Selank, pinealon and GHK-Cu/epithalon/CJC-1295 blends9
Vitamin and wellness shotsGlutathione, NAD+, Lipo-B, Lipo-C4
Groupings and counts by our calculation from the product filter on the Greenwich Rx recall page; some blends could fit more than one group. Check the official list for exact lots.

The mix tells its own story. Alongside compounded versions of the two best-known weight-loss molecules sit many peptides that are popular in longevity, recovery and wellness clinics but are not FDA-approved drugs. Interest in that category has surged this year, as we covered in our look at the Hims & Hers peptides launch and BPC-157 access. A recall of this breadth is a reminder that demand has grown faster than the quality infrastructure behind some suppliers.

How to check whether your vial is affected

  1. Look at the pharmacy name on your label. If it says Greenwich Rx or Clove Rx and the medicine was dispensed between August 10 and September 21, 2026, keep going.
  2. Open the official Greenwich Rx recall list, filter by product and pharmacy, and match the strength, lot number and beyond-use date.
  3. If it matches, stop using it and discard it. The FDA has guidance on safe disposal of unused medicines.
  4. Clove Rx customers should check the list even without a letter. Greenwich Rx is mailing its own customers but says Clove Rx patients may not get direct notice.
  5. Questions go to Sedgwick, the recall administrator, at 888-243-5547 on weekdays, 8 a.m. to 5 p.m. Eastern.

If you are on a weekly GLP-1 schedule, do not simply skip doses without a plan. Talk to the prescriber who ordered the medicine about a replacement supply. Anyone who notices redness, swelling, warmth or pus at an injection site, or develops fever or chills after an injection, should seek medical care promptly and mention the recall.

The bigger picture: compounded GLP-1s under pressure

Compounded semaglutide and tirzepatide boomed during the shortages of Wegovy, Ozempic, Zepbound and Mounjaro. With those shortages over, the FDA has narrowed what compounders may legally make, and drugmakers have cut cash prices for the branded products, as seen in Novo Nordisk’s $149 to $399 Wegovy pricing. Compounders have often responded by adding vitamins or amino acids such as B12 or glycine to create “personalised” blends, which is exactly what appears on this recall list.

Sterility lapses are a recurring theme in the sector. The FDA has issued a series of warning letters to compounders and telehealth suppliers this year, and several earlier 2026 recalls involved compounded injectables. For patients, the practical lesson is that a lower price can come with less visibility into how the drug was made. Branded GLP-1s are produced under full manufacturing rules that compounded versions are not required to meet.

Market context

Compounding is no longer a niche. Acumen Research and Consulting projected the global compounding pharmacies market would reach around US$14.3 billion in 2026, growing at about 6.2% a year, with North America the largest region. That report was last updated in February 2020, before the GLP-1 compounding wave, so treat the figure as dated and indicative; the weight-loss boom has likely reshaped the market since. Acumen also found that non-sterile formulations held the largest share, which puts sterile injectables like these in a smaller but higher-risk slice of the business.

What is still unknown

Neither the FDA notice nor the company statement says how many vials or patients are involved, what the inspectors observed, or which prescribers and telehealth brands routed orders through Clove Rx. The FDA has not yet published an inspection report or classified the recall. We will update this story if the agency releases more detail or if any infections are linked to the products. Readers following recalls can also see our coverage of the Whole Foods ashwagandha recall and other pharmaceutical news.

FAQ

Is compounded tirzepatide from Greenwich Rx recalled?

Yes, specific lots are. The list includes tirzepatide combined with B12, glycine, L-carnitine or methylcobalamin. Only lots dispensed between August 10 and September 21, 2026 and still within their beyond-use date are covered, so check your lot number.

What is Clove Rx and why is it in the recall?

Clove Rx is another pharmacy that had Greenwich Rx compound some products for it. Patients who received medicine through Clove Rx should review the recall list even if they have not received a letter.

Has anyone been harmed by the recalled injections?

Greenwich Rx says it has received no adverse event reports and found no contamination. The recall is precautionary, based on sterility assurance concerns raised after an FDA inspection.

Can I get a refund for a recalled Greenwich Rx product?

The announcement does not describe refunds. Contact Sedgwick at 888-243-5547 or the dispensing pharmacy to ask about replacement or reimbursement.

Sources: FDA company announcement and the Greenwich Rx recall notice, November 20, 2026. Market data: Acumen Research and Consulting. This article is for information only and is not medical advice. Last updated November 21, 2026.

Leave a Comment

Comments

No comments yet. Why don’t you start the discussion?

    Leave a Reply

    Your email address will not be published. Required fields are marked *